Biomarin Pharmaceutical (BMRN) Current Deferred Tax Assets: 2010-2015
Historic Current Deferred Tax Assets for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Sep 2015 value amounting to $30.9 million.
- Biomarin Pharmaceutical's Current Deferred Tax Assets rose 5.94% to $30.9 million in Q3 2015 from the same period last year, while for Sep 2015 it was $30.9 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of $31.2 million for FY2014, which is 2.09% up from last year.
- As of Q3 2015, Biomarin Pharmaceutical's Current Deferred Tax Assets stood at $30.9 million, which was down 1.04% from $31.2 million recorded in Q2 2015.
- Over the past 5 years, Biomarin Pharmaceutical's Current Deferred Tax Assets peaked at $32.4 million during Q4 2012, and registered a low of $16.7 million during Q2 2011.
- Over the past 3 years, Biomarin Pharmaceutical's median Current Deferred Tax Assets value was $30.6 million (recorded in 2014), while the average stood at $30.6 million.
- Per our database at Business Quant, Biomarin Pharmaceutical's Current Deferred Tax Assets spiked by 53.24% in 2012 and then declined by 9.58% in 2014.
- Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Current Deferred Tax Assets stood at $21.1 million in 2011, then soared by 53.24% to $32.4 million in 2012, then dropped by 5.55% to $30.6 million in 2013, then rose by 2.09% to $31.2 million in 2014, then increased by 5.94% to $30.9 million in 2015.
- Its Current Deferred Tax Assets was $30.9 million in Q3 2015, compared to $31.2 million in Q2 2015 and $31.2 million in Q1 2015.